Table 3. Changes in clinical and laboratory parameters from baseline to end of treatment (safety analysis set).
| Variable | Placebo (n=39) | Ipragliflozin (n=43) | P valuea |
|---|---|---|---|
| SBP, mm Hg | 2.5±12.98 | −9.6±14.72 | <0.001 |
| DBP, mm Hg | 0.5±8.33 | −5.9±10.23 | 0.003 |
| Pulse rate, /min | −0.6±9.24 | −2.1±8.16 | 0.429 |
| eGFR, mL/min/1.73 m2 | −7.62±32.34 | −3.39±30.62 | 0.545 |
| Total cholesterol, mg/dL | 10.5±24.88 | 0.2±25.99 | 0.072 |
| HDL-C, mg/dL | 0.4±6.02 | 3.9±6.62 | 0.014 |
| LDL-C, mg/dL | 7.2±23.89 | −2.4±29.67 | 0.114 |
| Triglycerides, mg/dL | 11.3±98.60 | −29.2±77.49 | 0.041 |
| Free fatty acids, mEq/L | −0.036±0.205 | −0.020±0.212 | 0.723 |
Values are presented as mean±standard deviation.
SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.
aTwo-sample t-test.